Efficacy of Umbilical Cord Cleansing With a Single Application of 4% Chlorhexidine for the Prevention of Newborn Infections in Uganda: a Randomized Controlled Trial
Primary Purpose
Omphalitis, Septicaemia
Status
Unknown status
Phase
Phase 4
Locations
Uganda
Study Type
Interventional
Intervention
Intervention arm: 4% chlorhexidine
Sponsored by
About this trial
This is an interventional prevention trial for Omphalitis
Eligibility Criteria
Inclusion Criteria:
- Newborns weighing 1.5kg or more at birth
- Newborns born to mothers whose HIV I status is negative
Exclusion Criteria:
- Newborns with severe congenital anomalies
- Newborns with infection of the umbilical cord at birth
- Twins or triplets
- Severely ill infants requiring hospitalization immediately after birth
- Children of mothers who cannot appropriately give consent within 12 h of birth
Sites / Locations
- Health Centers in Mukono and Kampala districtsRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention arm: 4% chlorhexidine
Control arm: Dry cord care
Arm Description
Neonates randomized to the chlorhexidine arm will have umbilical stump cleansing with a single application of 4% chlorhexidine solution at birth
Neonates randomized to the control arm will receive the current standard of cord care (dry cord care)
Outcomes
Primary Outcome Measures
Proportion of infants with severe illness
Severe illness will be defined as an acute illness that is associated with any of the following danger signs observed or verified by a study clinician: inability to feed or vomiting of everything and unable to keep anything down, lethargy or unconsciousness, severe lower chest in-drawing, axillary temperature of ≥38.0 degrees Celsius or <35.5 degrees Celsius, grunting, cyanosis, convulsions or a history of convulsions, and/or results in hospitalization and/or results in death. Hospitalization and death resulting from violent injury or burns will not contribute to the severe illness definition.
Proportion of infants with omphalitis
This outcome will be recorded as present or absent based on specific signs. These include: pus, redness (inflammation) and swelling (oedema) of the cord stump and the surrounding skin at its base. Swelling and redness will be further broken down into: none, mild, moderate and severe. No swelling or redness will be the absence of visible swelling or redness; mild swelling or redness as that limited to the cord stump only; moderate swelling or redness as that extending less than 2cm onto the abdominal skin at the base of the stump and severe swelling or redness as extending ≥2cm into the abdominal skin at the base of the stump. Pus will be defined as either present or absent. Cord infection will then be defined based on combinations of these recorded signs and their severity into four categories as follows: 1) redness extending to skin or pus, 2) moderate or severe redness, 3) moderate or severe redness with pus, or severe redness alone and 4) Severe redness with pus.
Secondary Outcome Measures
Death
Adverse events
Full Information
NCT ID
NCT02606565
First Posted
November 12, 2015
Last Updated
March 23, 2020
Sponsor
Makerere University
Collaborators
Centre For International Health
1. Study Identification
Unique Protocol Identification Number
NCT02606565
Brief Title
Efficacy of Umbilical Cord Cleansing With a Single Application of 4% Chlorhexidine for the Prevention of Newborn Infections in Uganda: a Randomized Controlled Trial
Official Title
Acceptability and Efficacy of Umbilical Cord Cleansing With 4% Chlorhexidine for the Prevention of Newborn Infections in Lira District, Northern Uganda: A Randomised Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
July 2016 (undefined)
Primary Completion Date
August 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Makerere University
Collaborators
Centre For International Health
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Background: Nearly all the yearly 3.3 million neonatal deaths occur in low and middle income countries. Infections, including those affecting the umbilical cord (omphalitis) are a significant factor in approximately a third of these deaths. In fact, the odds of all-cause mortality are 46% higher among infants with umbilical cord infection than those without infection. Five large randomized controlled trials in Asia and Sub-Saharan Africa have examined the effect of multiple applications (for at least 7 days) of 4% chlorhexidine (CHX) on the umbilical cord on omphalitis and neonatal death. These studies show a consitent positive effect of multiple applications on omphalitis but not on neonatal mortality. Whereas there is mounting evidence for the effect of 7 day chlorhexidine application, there is no data from Africa and only one study from Asia that examines the effect of a single application of CHX as soon as possible after birth. In this single Asian study, CHX led to a reduction in the risk of mild-moderate omphalitis and neonatal death. It is important, in an African setting to explore the effect of a single application, which is programmatically much simpler to implement than daily application for 7 days. Therefore, the investigators' study will compare umbilical cord cleansing with a single application of 4% chlorhexidine at birth with dry cord care in both community and facility births on omphalitis and severe illness in the neonatal period.
Methods: The chlorhexidine study is a community based, individually randomised controlled trial conducted on 4,760 mother-infant pairs in Uganda. The primary outcomes are severe illness and umbilical cord infection (omphalitis). Severe illness is defined as any illness associated with at least one of the following danger signs observed by study research assistants: inability to drink or breastfeed or (a history of) convulsions, lethargy or unconsciousness, vomiting of all feeds, and/or results in hospitalization and/or results in death.
Discussion: This study will provide novel evidence, from a Sub-Saharan African setting of the effect of umbilical cord cleansing with a single application of 4% chlorhexidine at birth in both community and facility births.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Omphalitis, Septicaemia
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
4760 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention arm: 4% chlorhexidine
Arm Type
Experimental
Arm Description
Neonates randomized to the chlorhexidine arm will have umbilical stump cleansing with a single application of 4% chlorhexidine solution at birth
Arm Title
Control arm: Dry cord care
Arm Type
No Intervention
Arm Description
Neonates randomized to the control arm will receive the current standard of cord care (dry cord care)
Intervention Type
Biological
Intervention Name(s)
Intervention arm: 4% chlorhexidine
Intervention Description
See previous description
Primary Outcome Measure Information:
Title
Proportion of infants with severe illness
Description
Severe illness will be defined as an acute illness that is associated with any of the following danger signs observed or verified by a study clinician: inability to feed or vomiting of everything and unable to keep anything down, lethargy or unconsciousness, severe lower chest in-drawing, axillary temperature of ≥38.0 degrees Celsius or <35.5 degrees Celsius, grunting, cyanosis, convulsions or a history of convulsions, and/or results in hospitalization and/or results in death. Hospitalization and death resulting from violent injury or burns will not contribute to the severe illness definition.
Time Frame
First 28 days of life
Title
Proportion of infants with omphalitis
Description
This outcome will be recorded as present or absent based on specific signs. These include: pus, redness (inflammation) and swelling (oedema) of the cord stump and the surrounding skin at its base. Swelling and redness will be further broken down into: none, mild, moderate and severe. No swelling or redness will be the absence of visible swelling or redness; mild swelling or redness as that limited to the cord stump only; moderate swelling or redness as that extending less than 2cm onto the abdominal skin at the base of the stump and severe swelling or redness as extending ≥2cm into the abdominal skin at the base of the stump. Pus will be defined as either present or absent. Cord infection will then be defined based on combinations of these recorded signs and their severity into four categories as follows: 1) redness extending to skin or pus, 2) moderate or severe redness, 3) moderate or severe redness with pus, or severe redness alone and 4) Severe redness with pus.
Time Frame
First 28 days of life
Secondary Outcome Measure Information:
Title
Death
Time Frame
First 28 days of life
Title
Adverse events
Time Frame
First 28 days of life
10. Eligibility
Sex
All
Maximum Age & Unit of Time
2 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Newborns weighing 1.5kg or more at birth
Newborns born to mothers whose HIV I status is negative
Exclusion Criteria:
Newborns with severe congenital anomalies
Newborns with infection of the umbilical cord at birth
Twins or triplets
Severely ill infants requiring hospitalization immediately after birth
Children of mothers who cannot appropriately give consent within 12 h of birth
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Victoria Nankabirwa, MD, MPH, PhD
Phone
+256755757460
Email
nankabirwav@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Victoria Nankabirwa, MD, MPH, PhD
Organizational Affiliation
Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Makerere University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Health Centers in Mukono and Kampala districts
City
Kampala
Country
Uganda
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Victoria Nankabirwa, MBChB, MPH, PhD
Phone
+256755757460
Email
nankabirwav@gmail.com
First Name & Middle Initial & Last Name & Degree
Josephine Tumuhamye, BBLT, MICM
Phone
0702063261
Email
tphynne@gmail.com
First Name & Middle Initial & Last Name & Degree
Victoria Nankabirwa, PhD
First Name & Middle Initial & Last Name & Degree
Halvor Sommerfelt, PhD
First Name & Middle Initial & Last Name & Degree
Grace Ndeezi, PhD
First Name & Middle Initial & Last Name & Degree
James Tumwine, PhD
First Name & Middle Initial & Last Name & Degree
Thorkild Tylleskar, PhD
12. IPD Sharing Statement
Citations:
PubMed Identifier
23728678
Citation
Imdad A, Bautista RM, Senen KA, Uy ME, Mantaring JB 3rd, Bhutta ZA. Umbilical cord antiseptics for preventing sepsis and death among newborns. Cochrane Database Syst Rev. 2013 May 31;2013(5):CD008635. doi: 10.1002/14651858.CD008635.pub2.
Results Reference
result
PubMed Identifier
28701228
Citation
Nankabirwa V, Tylleskar T, Tumuhamye J, Tumwine JK, Ndeezi G, Martines JC, Sommerfelt H. Efficacy of umbilical cord cleansing with a single application of 4% chlorhexidine for the prevention of newborn infections in Uganda: study protocol for a randomized controlled trial. Trials. 2017 Jul 12;18(1):322. doi: 10.1186/s13063-017-2050-0.
Results Reference
derived
Learn more about this trial
Efficacy of Umbilical Cord Cleansing With a Single Application of 4% Chlorhexidine for the Prevention of Newborn Infections in Uganda: a Randomized Controlled Trial
We'll reach out to this number within 24 hrs